384 related articles for article (PubMed ID: 17024483)
1. Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment.
Yeh CN; Chen TW; Liu FY; Jan YY; Chen MF
Langenbecks Arch Surg; 2006 Nov; 391(6):615-21. PubMed ID: 17024483
[TBL] [Abstract][Full Text] [Related]
2. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
Hong JL; Li J; Li J; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
[TBL] [Abstract][Full Text] [Related]
3. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
4. Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment.
Koyama T; Nimura H; Kobayashi K; Marushima H; Odaira H; Kashimura H; Mitsumori N; Yanaga K
Gastric Cancer; 2006; 9(3):235-9. PubMed ID: 16952044
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.
Yeh CN; Chen TW; Wu TJ; Hsueh S; Jan YY
World J Gastroenterol; 2006 Jun; 12(23):3760-5. PubMed ID: 16773696
[TBL] [Abstract][Full Text] [Related]
6. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.
Wang CM; Huang K; Zhou Y; Du CY; Ye YW; Fu H; Zhou XY; Shi YQ
J Cancer Res Clin Oncol; 2010 Jul; 136(7):1065-71. PubMed ID: 20043176
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP
Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal stromal tumors of the stomach.
Bennett JJ; Rubino MS
Surg Oncol Clin N Am; 2012 Jan; 21(1):21-33. PubMed ID: 22098829
[TBL] [Abstract][Full Text] [Related]
10. C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients.
Gao J; Dang Y; Sun N; Li J; Shen L
Med Oncol; 2012 Dec; 29(5):3039-45. PubMed ID: 22815156
[TBL] [Abstract][Full Text] [Related]
11. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
Lee JH; Kim Y; Choi JW; Kim YS
J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
[TBL] [Abstract][Full Text] [Related]
12. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
Heinrich MC; Owzar K; Corless CL; Hollis D; Borden EC; Fletcher CD; Ryan CW; von Mehren M; Blanke CD; Rankin C; Benjamin RS; Bramwell VH; Demetri GD; Bertagnolli MM; Fletcher JA
J Clin Oncol; 2008 Nov; 26(33):5360-7. PubMed ID: 18955451
[TBL] [Abstract][Full Text] [Related]
13. Emergence of imatinib resistance associated with downregulation of c-kit expression in recurrent gastrointestinal stromal tumor (GIST): optimal timing of resection.
Dudeja V; Armstrong LH; Gupta P; Ansel H; Askari S; Al-Refaie WB
J Gastrointest Surg; 2010 Mar; 14(3):557-61. PubMed ID: 20033343
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
15. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO
Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971
[TBL] [Abstract][Full Text] [Related]
16. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.
Tamborini E; Bonadiman L; Greco A; Albertini V; Negri T; Gronchi A; Bertulli R; Colecchia M; Casali PG; Pierotti MA; Pilotti S
Gastroenterology; 2004 Jul; 127(1):294-9. PubMed ID: 15236194
[TBL] [Abstract][Full Text] [Related]
17. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
Desai J; Shankar S; Heinrich MC; Fletcher JA; Fletcher CD; Manola J; Morgan JA; Corless CL; George S; Tuncali K; Silverman SG; Van den Abbeele AD; van Sonnenberg E; Demetri GD
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5398-405. PubMed ID: 17875769
[TBL] [Abstract][Full Text] [Related]
18. Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case.
Utsunomiya T; Okamoto M; Yano S; Kameyama T; Matsuyama A; Kuma S; Yamamoto M; Fujiwara M; Ishida T
Surg Today; 2008; 38(1):65-7. PubMed ID: 18085368
[TBL] [Abstract][Full Text] [Related]
19. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
[TBL] [Abstract][Full Text] [Related]
20. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.
Yeh CN; Chen TW; Tseng JH; Liu YY; Wang SY; Tsai CY; Chiang KC; Hwang TL; Jan YY; Chen MF
J Surg Oncol; 2010 Nov; 102(6):599-603. PubMed ID: 20976730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
